May 17, 2021
Article
The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.
Video
The senior director of patient management, care, and rehabilitation research at the National MS Society discussed challenges in care and rehabilitation in patients with progressive MS.
Robert Fox, MD, Vice-Chair for Research at the Cleveland Clinic Neurological Institute, discussed the findings of the phase 2 EMPhASIS trial of this investigational MS therapy.
Nearly 65% of responders say their migraine disease makes them feel like life is passing them by and more than half claimed they cannot make plans with friends or family because of the unpredictability of their disease.
The assistant professor of neurology at the Keck School of Medicine at University of Southern California shared her insight into the study data and the therapy’s potential advantages for patients with Parkinson disease.
Here's what is coming soon to NeurologyLive.
May 16, 2021
The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed populations that exhibit greater practice effects than others.
The 2 organizations will use whole-genome sequencing and clinical characterization to investigate the genetic causes of CP.
May 15, 2021
Future steps, including plans for global studies, are currently being evaluated by Biogen, with the final results from the phase 2a study expected to be released in an upcoming scientific forum.
The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.
